HIV-1 Aptamer Binding Poly-A Hairpin via Segmentation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current aptamers targeting HIV-1's 5'UTR are limited by their ability to bind effectively due to steric hindrance from adjacent regions and subdomains, and the production process does not account for the structural balance between the 5'UTR's conformers, which affects their binding capacity.
Innovation Solution
Development of aptamers through a combined in vitro selection and bioinformatic analysis approach that targets the complete 308 nt of the HIV-1 5'UTR, specifically binding to the Poly-A domain, which is conserved across viral isolates, using a novel octanucleotide motif (5'-GGCARGGA-3') and flanking regions to enhance binding efficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If aptamers are designed to target the 5'UTR region of HIV-1, then binding specificity to viral genomic regions is improved, but steric hindrance from adjacent regions and subdomains reduces binding effectiveness
Solution Approach 1:
The invention divides the 5'UTR region into distinct functional domains (TAR, Poly-A, DIS, SL) and designs aptamers that specifically target individual domains rather than the entire region. This segmentation allows the aptamers to bind to specific targets without steric interference from adjacent viral RNA structures, resolving the contradiction between binding specificity and effectiveness
Solution Approach 2:
The patent creates aptamers with localized binding properties that match the specific structural characteristics of each 5'UTR domain. Each aptamer is optimized for its target domain's local structure (e.g., TAR's stem-loop, Poly-A's polyadenylate tract), enabling high-affine binding that overcomes steric hindrance by adapting to the local geometric and chemical environment
2Adaptability or versatility
If the complete 308 nt of 5'UTR is used as target in selection process, then aptamers bind to conserved regions across viral isolates, but the structural balance between 5'UTR conformers (LDI and BMH) affects binding capacity
Solution Approach 1:
The invention accounts for the dynamic conformational equilibrium between LDI and BMH structures of the 5'UTR. The selection process and aptamer design consider that these conformers interconvert and that functional domains are exposed differently in each conformation. This dynamic approach enables the development of aptamers that can bind effectively across different viral isolates while accounting for conformational flexibility
Solution Approach 2:
The patent optimizes selection conditions and aptamer parameters (sequence, length, structure) to account for conformational dynamics. By adjusting selection stringency, temperature, and aptamer design parameters, the process identifies aptamers that maintain binding capacity despite conformational changes, achieving broad-spectrum activity while preserving reliable binding
3Ease of manufacture
If conventional in vitro selection is used for aptamer production, then aptamers can be generated, but the process does not account for structural balance between 5'UTR conformers, limiting binding efficiency
Solution Approach 1:
The invention incorporates preliminary considerations of 5'UTR conformational dynamics into the aptamer selection process. Before actual selection, the structural characteristics and conformer balance of the target 5'UTR are analyzed, and selection conditions are pre-optimized to favor the exposure of functional domains. This preliminary preparation ensures that subsequent selection yields aptamers with high binding efficiency, bridging the gap between ease of manufacture and manufacturing precision
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The aptamers demonstrate high specificity and efficiency in binding to the HIV-1 5'UTR, inhibiting viral replication in cell culture, and are effective against a broad spectrum of HIV-1 isolates, including those with different subtypes and recombinant forms.
Implementation Method 1
aptamers... specifically binding to the Poly-A domain... binding to the HIV-1 5'UTR
Data Source
Figure 1
Figure 1
Figure 2
AI summary
The invention relates to an aptamer, the structure thereof comprising at least one nucleotide sequence 5'-GGCA(A/G)GGA-3', that can specifically bind to the poly(A) hairpin of the 5'UTR region of the genome of the human immunodeficiency virus type 1 (HIV-1), providing the method for producing aptamers with said sequence by means of a combination of experimental techniques of in vitro selection of nucleic acids with computational techniques of sequence optimization. The invention also relates to a DNA gene structure for synthesizing said aptamers, preferably RNA. The invention further relates to the different uses of the above-mentioned aptamer, including the use thereof as a biosensor molecule for detecting and/or quantifying HIV-1, as an inhibitor of the production of viral particles of HIV-1, and to the application thereof in medicine, the invention also relating to a method for treating a disease caused by HIV-1, and to a pharmaceutical composition comprising said aptamer.